Shopping Cart
- Remove All
Your shopping cart is currently empty
DN-1289
🥰Excellent
Catalog No. T73457
DN-1289 is an orally available, blood-brain barrier-crossing, selective and potent inhibitor with an IC50 value of 17 nM for di-leucine zipper kinase (DLK) and 40 nM for leucine zipper-bearing kinase (LZK).DN-1289 significantly inhibited optic nerve crush (ONC)-induced p-c-Jun in a mouse model.
DN-1289
🥰Excellent
Purity: 98.56%
Catalog No. T73457
DN-1289 is an orally available, blood-brain barrier-crossing, selective and potent inhibitor with an IC50 value of 17 nM for di-leucine zipper kinase (DLK) and 40 nM for leucine zipper-bearing kinase (LZK).DN-1289 significantly inhibited optic nerve crush (ONC)-induced p-c-Jun in a mouse model.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $78 | In Stock | |
| 5 mg | $189 | In Stock | |
| 10 mg | $297 | In Stock | |
| 25 mg | $619 | In Stock | |
| 50 mg | $993 | In Stock | |
| 100 mg | $1,590 | In Stock |
Add to Cart
Add to Quotation
Bulk & Custom
This molecule is a custom-made product. TargetMol has an excellent synthesis team with the experience and capability to provide you with cost-effective products. However, due to objective factors, there is a small probability that the synthesis may not be successful during the R&D process. We appreciate your understanding. If you have any questions, please feel free to contact us. We are committed to serving you wholeheartedly.
Questions
View MoreBatch Information
Select Batch
Purity:98.56%
ee:100%
Contact us for more batch information
Product Introduction
Bioactivity
Chemical Properties
| Description | DN-1289 is an orally available, blood-brain barrier-crossing, selective and potent inhibitor with an IC50 value of 17 nM for di-leucine zipper kinase (DLK) and 40 nM for leucine zipper-bearing kinase (LZK).DN-1289 significantly inhibited optic nerve crush (ONC)-induced p-c-Jun in a mouse model. |
| In vitro | DN-1289 (Compound 14) (0.1, 0.3, and 1 μM; 0-20 h) can block the neurite degeneration induced by nerve growth factor (NGF) withdrawal in dorsal root ganglion (DRG) neurons[1]. DN-1289 (0.1, 0.3, and 1 μM; 0-20 h) inhibits the activation of caspases, apoptotic protease, in NGF withdrawal-induced apoptosis in DRG neurons[1]. |
| In vivo | DN-1289 (Compound 14) demonstrates good tolerance in a mouse model at doses of 100 mg/kg and 150 mg/kg administered via intraperitoneal injection once daily for 10-15 days[1]. DN-1289 (150 mg/kg; oral administration; twice daily for 10 days) inhibits c-Jun phosphorylation in the acute optic nerve crush (ONC) injury model[1]. |
| Molecular Weight | 441.38 |
| Formula | C18H19F4N7O2 |
| Smiles | NC1=C(OC(F)F)N=C(C2=NC(N3[C@@H]4CO[C@H](C3)C4)=NC(N5CC(F)(CC5)F)=C2)C=N1 |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 55 mg/mL (124.61 mM), Sonication is recommended.  | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.53 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% Saline/PBS/ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Sci Citations
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy DN-1289 | purchase DN-1289 | DN-1289 cost | order DN-1289 | DN-1289 chemical structure | DN-1289 in vivo | DN-1289 in vitro | DN-1289 formula | DN-1289 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.